Results 151 to 160 of about 738,105 (258)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Potential Feasibility and Perspectives of Fecal Microbiota Transplantation for Restoring Gut Function in Giant Pandas. [PDF]

Animals (Basel)
Fu L, Xue Y, Wang Y, Zhao S, Wang Q, Che H.   +5 more
europepmc   +1 more source

Fecal Microbiota Transplantation: Ethical Challenges and Regulatory Hurdles

, 2016
On Tuesday, March 8, 2016, the Consortium on Law and Values hosted the second installment of the "Microbiome Research & Microbiota Therapeutics" Lecture Series.

core  

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Safety of Fecal Microbiota Transplantation in Children: A Single-Center Experience. [PDF]

Children (Basel)
Varnas D, Urbonas V.
europepmc   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

The selection of matching donors for patients in fecal microbiota transplantation. [PDF]

Front Microbiol
Qian X, Wu Y, Wang W, Shao H, Xu Z.
europepmc   +1 more source

Tigecycline combination therapy for fulminant Clostridioides difficile infection: an Australian experience

Internal Medicine Journal, EarlyView.
Abstract Background Recent European Society of Clinical Microbiology and Infection and Australasian Society of Infectious Diseases Clostridioides difficile infection (CDI) management guidelines endorse the addition of intravenous tigecycline in patients who are progressing to fulminant infection.
Emma Bishop, Tanya Ravipati, Steven Mileto, Eugene Athan, Dena Lyras, Ravindranath Tiruvoipati   +5 more
wiley   +1 more source

Cohesive modules of engraftment in fecal microbiota transplantation. [PDF]

iScience
Rashidi A, Minot SS, Lee SJ, Hill GR, Podlesny D.   +4 more
europepmc   +1 more source